Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)
- Authors:
- Hiu Yan Jennifer Lee
- Mingjing Meng
- Yulong Liu
- Tao Su
- Hiu Yee Kwan
-
Affiliations: School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SAR, P.R. China, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China - Published online on: July 8, 2021 https://doi.org/10.3892/ol.2021.12907
- Article Number: 646
This article is mentioned in:
Abstract
 |
|
Cao M and Chen W: Epidemiology of lung cancer in China. Thoracic Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–3000. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M and Sørensen JB: Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Differences and similarities with acquired resistance. Cancers (Basel). 11:9232019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z: ErbB receptors and cancer. Methods Mol Biol. 1652:3–35. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wu Y, Dong M, He X, Wang Z, Li J and Wang Y: Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-cancer Drugs. 27:245–250. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, et al: Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 75:1335–1348. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Camidge DR, Pao W and Sequist LV: Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol. 11:473–481. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489(519): 20122012. | |
|
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen RN, Zhang Y, Seal B, Ryan K, Yong C, Darilay A and Ramsey SD: Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: A SEER cancer registry analysis. BMC Cancer. 20:2762020. View Article : Google Scholar : PubMed/NCBI | |
|
Sui X, Zhang M, Han X, Zhang R, Chen L, Liu Y, Xiang Y and Xie T: Combination of traditional Chinese medicine and epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine (Baltimore). 99:e206832020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao L, Xu J, Sun J, Chen Z, Gong Y, Bi L, Lu Y, Yao J, Zhu W, Hou A, et al: Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): A multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 10:7322019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, Chen JX and Shen XH: Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: A systematic review and meta-analysis. J Integr Med. 12:346–358. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li CL, Hsia TC, Li CH, Chen KJ, Yang YH and Yang ST: Adjunctive traditional Chinese medicine improves survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A nationwide, population-based cohort study. Integr Cancer Ther. 18:15347354198270792019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XB, Wu WY, Long SQ, Deng H and Pan ZQ: Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective case-control study. Complement Ther Med. 22:1010–1018. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang M, Wang S, Zhao B, Wang W, Zhu Y, Hu L, Zhang X and Xiong S: Traditional Chinese medicine prolongs progression-free survival and enhances therapeutic effects in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations. Med Sci Monit. 25:8430–8437. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CY, Huang HS, Su YC, Tu CY, Hsia TC and Huang ST: Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer. Complement Ther Med. 40:29–36. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bing Z, Cheng Z, Shi D, Liu X, Tian J, Yao X, Zhang J, Wang Y and Yang K: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. BMC Complement Altern Med. 18:2932018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Jiang X, Xu Z, Ye T and Shi Q: The efficacy of Brucea javanica oil emulsion injection as adjunctive therapy for advanced non-small-cell lung cancer: A meta-analysis. Evid Based Complement Alternat Med. 2016:59285622016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Liu CY, Fan PW, Hsieh CH, Lin HY, Lee MC and Fang K: The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor. Drug Des Devel Ther. 10:3599–3609. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ji ZQ, Huang XE, Wu XY, Liu J, Wang L and Tang JH: Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev. 15:8603–8605. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Han SY, Zhao MB, Zhuang GB and Li PP: Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer. 75:30–37. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Han SY, Zhao W, Sun H, Zhou N, Zhou F, An G and Li PP: Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Phytomedicine. 22:560–567. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Choi YJ, Kim JH, Rho JK, Kim JS, Choi CM, Kim WS, Son J and Lee JC: AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncol Rep. 37:2201–2208. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Han SY, Sun H, Xue D, Zhao W, Jiao YN and Li PP: Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by Marsdenia tenacissima extract. AACR. Jul 17–2017.(Epub ahead of print). doi: 10.1158/1538-7445.AM2017-1199. | |
|
Deng J, Shen F and Chen D: Quantitation of seven polyoxypregnane glycosides in Marsdenia tenacissima using reversed-phase high-performance liquid chromatography-evaporative light-scattering detection. J Chromatogr A. 1116:83–88. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen B, Wang Z, Zhang W, Hao K, Chen Y, Li K, Wang T, Xie Y, Huang Z and Tong X: Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. Oncotarget. 7:82851–82863. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Zhong R, Huang H, Zhang Z, Ding D, Yan H, Sun E and Jia X: Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells. Nutr Cancer. 66:682–689. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Wang X, Zhang DW, Wang NL and Yao XS: Nonflavanoid compounds from Epimedium koreanum. Chin Tradit Herb Drugs. 38:1135–1138. 2007.PubMed/NCBI | |
|
Yu X, Tong Y, Han XQ, Kwok HF, Yue GG, Lau CB and Ge W: Anti-angiogenic activity of herba epimedii on zebrafish embryos in vivo and HUVECs in vitro. Phytother Res. 27:1368–1375. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N and Sharifi-Rad J: Resveratrol: A Double-Edged sword in health benefits. Biomedicines. 6:912018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, He W, Gao X, Li B, Mei C, Xu R and Chen H: Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Sci Rep. 5:177302015. View Article : Google Scholar : PubMed/NCBI | |
|
Nam B, Rho JK, Shin D and Son J: Gallic acid induces apoptosis in EGFR-mutant non-small cell lung cancers by accelerating EGFR turnover. Bioorg Med Chem Lett. 26:4571–4575. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Phan AN, Hua TN, Kim MK, Vo VT, Choi JW, Kim HW, Rho JK, Kim KW and Jeong Y: Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget. 7:54702–54713. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H, Qiao F, Wang Y, Xu Y and Shang Y: Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol Rep. 34:2782–2789. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Y, Wei C and Xi Z: Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway. In Vitro Cell Dev Biol Anim. 50:840–850. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Chao Y, Fang Y, Wang J, Wang M, Zhang H, Ying M, Zhu X and Wang H: MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. J Exp Clin Cancer Res. 32:332013. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao K, Jiang J, Guan C, Dong C, Wang G, Bai L, Sun J, Hu C and Bai C: Curcumin induces autophagy via activating the AMPK signaling pathway in lung adenocarcinoma cells. J Pharmacol Sci. 123:102–109. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Lee Y, Chang G, Yu SL, Hsieh WY, Chen JJ, Chen HW and Yang PC: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy. PLoS One. 6:e237562011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Huang H, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG and Li J: Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J Exp Clin Cancer Res. 38:2542019. View Article : Google Scholar : PubMed/NCBI | |
|
Yamauchi Y, Izumi Y, Yamamoto J and Nomori H: Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells. Phytother Res. 28:728–735. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tran K, Merika M and Thanos D: Distinct functional properties of IkappaB alpha and IkappaB beta. Mol Cell Biol. 17:5386–5399. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H and Jiang L: Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncol Res. 21:137–144. 2014. View Article : Google Scholar | |
|
Ye MX, Zhao YL, Li Y, Miao Q, Li ZK, Ren XL, Song LQ, Yin H and Zhang J: Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomedicine. 19:779–787. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y and Nimmannit U: Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest. 27:624–635. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng M, Xin Y, Li Y, Xu F, Xi X, Guo H, Cui X, Cao H, Zhang X and Han C: Ginsenosides: A potential neuroprotective agent. Biomed Res Int. 2018:81743452018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Zuo L, Guo D, Chai X, Xu J, Cui Z, Wang Z and Hou C: Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomed Pharmacother. 120:1094832019. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Y, Wang W, Sun Q and Tuohayi J: Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines. Exp Ther Med. 17:953–959. 2018.PubMed/NCBI | |
|
Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Wang J, Wang X, Wei N, Liu H and Zhang X: CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer. Clin Respir J. 13:23–33. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Q, Lin S, Zeng Y, Yao M, Liu K, Yuan H, Liu C and Jiang G: Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells. Environ Toxicol. 35:643–651. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu T, Jin Z, Yuan Y, Wei H, Xu X, He S, Chen S, Hou W, Guo Q and Hua B: Ginsenoside Rg3 serves as an adjuvant chemotherapeutic agent and VEGF inhibitor in the treatment of non-small cell lung cancer: A meta-analysis and systematic review. Evid Based Complement Alternat Med. 2016:78267532016. View Article : Google Scholar : PubMed/NCBI | |
|
Chian S, Zhao Y, Xu M, Yu X, Ke X, Gao R and Yin L: Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Anticancer Drugs. 30:838–845. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Yang Y, Yang Y, Zhang Y, Yue Z, Pan Z and Ren X: Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomed Pharmacother. 96:378–383. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dai P, Liu D, Zhang L, Ye J, Wang Q, Zhang HW, Lin XH and Lai GX: Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumor Biol. Apr 26–2017.(Epub ahead of print). doi: 10.1177/1010428317697555. View Article : Google Scholar | |
|
Yang Q, Chen W, Xu Y, Lv X, Zhang M and Jiang H: Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol. 356:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Xiao G, Chen Y and Deng Y: LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Anticancer Drugs. 29:725–735. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Mei Z, Hu H and Zhang X: The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 233:6679–6688. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P and Tassone P: MALAT1: A druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 11:632018. View Article : Google Scholar : PubMed/NCBI | |
|
Harada D, Takigawa N and Kiura K: The role of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xu YH and Lu S: A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol. 40:311–317. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zulkifli AA, Tan FH, Putoczki TL, Stylli SS and Luwor RB: STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Mol Cell Endocrinol. 451:15–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng R, Jiang H, Li J, Liu X and Xu H: Polyphyllin II restores sensitization of the resistance of PC-9/ZD cells to gefitinib by a negative regulation of the PI3K/Akt/mTOR signaling pathway. Curr Cancer Drug Targets. 17:376–385. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Fei Z and Jiang H: Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer. J Pharmacol Sci. 134:190–196. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lou W, Chen Y, Zhu K, Deng H, Wu T and Wang J: Polyphyllin I overcomes EMT-associated resistance to erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition. Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Feng F, Cheng P, Sun C, Wang H and Wang W: Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Chin J Nat Med. 17:768–777. 2019.PubMed/NCBI | |
|
Feng F, Cheng P, Wang C, Wang Y and Wang W: Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis. Oncol Lett. 18:5428–5436. 2019.PubMed/NCBI | |
|
Wang YC, Wu DW, Wu TC, Wang L, Chen CY and Lee H: Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression. Int J Biol Sci. 14:47–56. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mainardi S, Mulerosanchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, et al: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med. 24:961–967. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Xu Y, Jin E, Zhu LC, Xia B, Chen XF, Li FZ and Ma SL: Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacol Sin. 38:100–109. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV and Gupta RC: Cucurbitacin B potently suppresses non-small-cell lung cancer growth: Identification of intracellular thiols as critical targets. Cancer Letters. 332:35–45. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, Liu L, Cheng X and Zeng W: Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 12:957–967. 2019.PubMed/NCBI | |
|
Wei L, Qu W, Sun J, Wang X, Lv L, Xie L and Song X: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin. Cancer Gene Therapy. 21:194–199. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA and Hahn WC: The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 129:969–982. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu P, Xiang Y, Liu X, Zhang T, Yang R, Chen S, Xu L, Yu Q, Zhao H, Zhang L, et al: Cucurbitacin B induces the lysosomal degradation of EGFR and suppresses the CIP2A/PP2A/Akt signaling axis in gefitinib-resistant non-small cell lung cancer. Molecules. 24:6472019. View Article : Google Scholar : PubMed/NCBI | |
|
Hong SH, Ku JM, Lim YS, Lee SY, Kim JH, Cheon C and Ko SG: Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs. Front Oncol. 10:622020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou G, Chen S, Wang Z and Chen Z: Back to the future of oridonin: Again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res. 17:274–276. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao X, He Z, Cao W, Cai F, Zhang L, Huang Q, Fan C, Duan C, Wang X, Wang J and Liu Y: Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol. 48:2608–2618. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget. 7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Wang Y, Dai SD and Wang EH: Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis. BMC Cancer. 11:1862011. View Article : Google Scholar : PubMed/NCBI | |
|
Jho EH, Zhang T, Domon C, Joo CK, Freund JN and Costantini F: Wnt/beta-Catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 22:1172–1183. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Shen R, Li J, Ye D, Wang Q and Fei J: Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma. Acta Biochim Biophys Sin (Shanghai). 48:894–901. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hong J, Jiang AY, Han W, Yong C, Yan W and Jiang XF: Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. Mol Med Rep. 16:3475–3481. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SF, Zhang ZY and Zhang JL: Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL-6/JAK1/STAT3 signaling pathway. Mol Med Rep. 16:2733–2739. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HQ, Jin JJ and Wang J: Matrine induces mitochondrial apoptosis in cisplatin-resistant non-small cell lung cancer cells via suppression of β-catenin/survivin signaling. Oncol Rep. 33:2561–2566. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Yu X, Tan S, Liu W, Zhou L and Liu H: Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway. Cancer Med. 7:208–218. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ, Leung EL, Chow LW and Liu L: Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. Pharmacol Res. 115:45–55. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HJ, Hwang KE, Park DS, Oh SH, Jun HY, Yoon KH, Jeong ET, Kim HR and Kim YS: Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells. J Transl Med. 15:1232017. View Article : Google Scholar : PubMed/NCBI | |
|
Li YL, Hu X, Li QY, Wang F and Zhang C: Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy. Mol Med Rep. 18:3882–3890. 2018.PubMed/NCBI | |
|
Tang JC, Ren YG, Zhao J, Long F, Chen JY and Jiang Z: Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway. Life Sci. 204:71–77. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kobierzycki C, Pula B, Werynska B, Piotrowska A, Muszczynska-Bernhard B, Dziegiel P and Rakus D: The lack of evidence for correlation of pyruvate kinase M2 expression with tumor grade in non-small cell lung cancer. Anticancer Res. 34:3811–3817. 2014.PubMed/NCBI | |
|
Guo ZL, Li JZ, Ma YY, Qian D, Zhong JY, Jin MM, Huang P, Che LY, Pan B, Wang Y, et al: Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways. BMC Cell Biol. 19:292018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Luo Z, Zhang H and Wang T: Tanshinone IIA reverses gefitinib-resistance in human non-small-cell lung cancer via regulation of VEGFR/Akt pathway. Onco Targets Ther. 12:9355–9365. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Meng X, Xu N, Fu W, Tan H, Zhang L, Zhou Q, Qian J, Tu S, Li X, et al: Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. Cell Death Dis. 9:2622018. View Article : Google Scholar : PubMed/NCBI | |
|
Mei W, Dong C, Hui C, Bin L, Fenggen Y, Jingjing S, Cheng P, Meiling S, Yawen H, Xiaoshan W, et al: Gambogenic acid kills lung cancer cells through aberrant autophagy. PLoS One. 9:e836042014. View Article : Google Scholar : PubMed/NCBI | |
|
Shen D, Wang Y, Niu H and Liu C: Gambogenic acid exerts anticancer effects in cisplatin-resistant non-small cell lung cancer cells. Mol Med Rep. 21:1267–1275. 2020.PubMed/NCBI | |
|
Ye J, Xue M, Qiu Z, Su Y, Yu P and Peng Q: Anti-tumor and anti-metastatic roles of cordycepin, one bioactive compound of Cordyceps militaris. Saudi J Biol Sci. 25:991–995. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tuli HS, Sandhu SS and Sharma AK: Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin. 3 Biotech. 4:1–12. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wu X, Liang YN, Wang L, Song ZX, Liu JL and Tang ZS: Cordycepin induces apoptosis and inhibits proliferation of human lung cancer cell line H1975 via Inhibiting the Phosphorylation of EGFR. Molecules. 21:12672016. View Article : Google Scholar : PubMed/NCBI | |
|
Hawley SA, Ross FA, Russell FM, Atrih A, Lamont DJ and Hardie DG: Mechanism of activation of AMPK by cordycepin. Cell Chem Biol. 27:214–222.e4. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wang X, Qu K, Zhu P, Guo N, Zhang R, Abliz Z, Yu H and Zhu H: Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation. Chem Biol Drug Des. 76:340–344. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wei C, Yao X, Jiang Z, Wang Y, Zhang D, Chen X, Fan X, Xie C, Cheng J, Fu J and Leung EL: Cordycepin inhibits drug-resistance non-small cell lung cancer progression by activating AMPK signaling pathway. Pharmacol Res. 144:79–89. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Byun S, Lee SY, Lee J, Jeong CH, Farrand L, Lim S, Reddy K, Kim JY, Lee MH, Lee HJ, et al: USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin Cancer Res. 19:3894–3904. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Zhao X, Li C, Liu S, Yan F, Teng Y, Feng J and Miao D: Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer. Human Cell. 32:360–366. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS and Olson AJ: Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protocols. 11:905–919. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Meng XY, Zhang HX, Mezei M and Cui M: Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 7:146–157. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC and Wong CH: Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Acad Sci USA. 112:6955–6960. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Li HH, Su F, Li J, Ma XP and Gong P: Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. Int J Clin Exp Pathol. 8:9010–9020. 2015.PubMed/NCBI | |
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 16:1172–1185. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dai M, Hu S, Liu CF, Jiang L, Yu W, Li ZL, Guo W, Tang R, Dong CY, Wu TH and Deng WG: BPTF cooperates with p50 NF-κB to promote COX-2 expression and tumor cell growth in lung cancer. Am J Transl Res. 11:7398–7409. 2019.PubMed/NCBI | |
|
Konson A, Mahajna JA, Danon A, Rimon G and Agbaria R: The involvement of nuclear factor-kappa B in cyclooxygenase-2 overexpression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 13:1093–1104. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shi G and Li D, Fu J, Sun Y, Li Y, Qu R, Jin X and Li D: Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma. Am J Transl Res. 7:1612–1620. 2015.PubMed/NCBI | |
|
Lee KY, Park JS, Jee YK and Rosen GD: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med. 34:462–468. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Woo JH, Li DP, Wilsbach K, Orita H, Coulter J, Tully E, Kwon TK, Xu S and Gabrielson E: Coix seed extract, a commonly used treatment for cancer in china, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther. 6:2005–2011. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu YL, Kuo PL and Lin CC: Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci. 75:2303–2316. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y, Shi RX, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Birt DF, Hendrich S and Wang WQ: Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase signaling to suppress human cancer cell growth. PLoS One. 8:e692402013. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai JR, Liu PL, Chen YH, Chou SH, Cheng YJ, Hwang JJ and Chong IW: Curcumin inhibits non-small cell lung cancer cells metastasis through the Adiponectin/NF-κb/MMPs signaling pathway. PLoS One. 10:e01444622015. View Article : Google Scholar : PubMed/NCBI | |
|
Wright C, Iyer AKV, Yakisich JS and Azad N: Anti-tumorigenic effects of resveratrol in lung cancer cells through modulation of c-FLIP. Curr Cancer Drug Targets. 17:669–680. 2017. View Article : Google Scholar : PubMed/NCBI |
